Memorial, TX Ketamine Therapy Clinic: Expert-Led Treatment for Depression, Anxiety, PTSD, and Chronic Pain That Traditional Medications Can't Reach

You’re not the kind of person who gives up easily. You researched your condition. You found a good psychiatrist — maybe through a referral from someone you trust. You took the medications as directed, gave each one the full timeline, and reported your responses accurately. You engaged in therapy with genuine effort. And still, you’re here. Not because you did something wrong. Because the pharmacological tools your providers had available all work within the same narrow corridor of brain chemistry — serotonin, norepinephrine, dopamine — and for your particular brain, that corridor doesn’t contain the answer.

Ketamine exits that corridor entirely. It engages the glutamate system — the brain’s largest and most active neural network — and initiates a form of repair that standard antidepressants can’t perform: the physical reconstruction of synaptic connections that chronic depression, anxiety, PTSD, and pain have degraded over time. UT Southwestern Medical Center, one of the nation’s premier academic medical institutions, identifies ketamine among its specialized therapies for severe and treatment-resistant depression, highlighting its ability to provide rapid-acting benefits for patients with serious depression and suicidal thoughts. Catalyst Health & Wellness delivers this treatment to the Memorial community through three Houston-area clinics, each under the direct supervision of Dr. Ho — a board-certified anesthesiologist and former pediatrician whose dual training provides the precise pharmacological management, continuous monitoring, and compassionate care that safe ketamine therapy requires.

Ketamine’s medical history predates its psychiatric role by decades. Synthesized in 1962 and FDA-approved as a general anesthetic in 1970, it became indispensable to surgical suites, emergency rooms, pediatric care, and battlefield medicine worldwide. More than fifty years and millions of administrations later, it carries one of the most exhaustively documented safety records in pharmacology.

The psychiatric breakthrough was serendipitous. In the late 1990s, researchers studying glutamate — the neurotransmitter responsible for the majority of excitatory brain signaling — observed that low-dose ketamine produced rapid, dramatic depression relief in patients who had exhausted conventional options. The timeline was hours, not weeks. The patients who responded most strongly were precisely the ones other treatments had failed.

The underlying biology has since been thoroughly mapped. Conventional antidepressants increase the availability of serotonin, norepinephrine, or dopamine and wait for the brain to adapt — four to eight weeks, when it happens. Ketamine skips that waiting period. By blocking NMDA receptors in the glutamate system, it triggers a cascade that releases brain-derived neurotrophic factor (BDNF), the growth protein that physically constructs new synapses in regions governing mood regulation, threat assessment, and pain processing. Chronic conditions structurally thin these connections. Ketamine restores them — often within a single treatment. This shared structural deficit across depression, anxiety, PTSD, OCD, chronic pain, and suicidal ideation explains why one mechanism simultaneously improves conditions that appear unrelated on the surface.